Anal canal cancer is a rare cancer both world-wide and in the Kingdom of Saudi Arabia (KSA). In 2010, a total of only 27 cases were diagnosed in KSA, 18 males and 9 females representing 0.3% of all cases diagnosed in the Saudi population.[@ref1] The age standardized rate was 0.3/100,000 for males and 0.2/100,000 for females.

The evidence adopted in these guidelines is rated at 3 levels: 1) Evidence level (EL)-1 (highest level) evidence from phase III randomized trials or meta-analyses; 2) EL-2 (intermediate-level) evidence from good phase II trials or phase III trials with limitations; and 3) EL-3 (low-level) from retrospective or observational data and/or expert opinion. This easy-to-follow grading system is convenient for the reader and allows accurate assessment of the applicability of the guidelines in individual patients.[@ref2]

All cases of anal canal cancer should preferably be seen or discussed in a multidisciplinary form.

**Pre-treatment evaluation**1.1History and clinical examination including inguinal lymph node palpation and rigid anoscopy1.2Blood count, liver, and renal function levels1.3Chest x-ray1.4Computed tomography (CT) scan of abdomen and pelvis1.5Magnetic resonance imaging (MRI) of pelvis1.6Fine needle aspiration of inguinal lymph nodes if clinically palpable1.7Human immunodeficiency virus testing in selected cases**Staging**The American Joint Commission on Cancer (AJCC)- 2007 pathological staging system will be used.[@ref3]**Treatment**3.1Localized disease (clinical stage T1-4, N0-1). Concurrent chemoradiotherapy[@ref4] (EL-2)3.1.1Chemotherapy: 5-fluorouracil and mitomycin C on day one and 29 of radiation therapy[@ref5] (EL-1). Alternatively, oral capecitabine at a dose of 825 mg/m^2^ twice daily on each day of radiation can be used[@ref6] (EL-3)3.1.2Radiotherapy: 45 Gy administered as 1.80 Gy per fraction in 25 fractions to the pelvis and inguinal node area + 5.4-9.0 Gy boost to the tumor bed[@ref7]3.2Localized disease (clinical stage T~any~ N2-3). Concurrent chemoradiotherapy[@ref8]3.2.1Chemotherapy: 5-fluorouracil and mitomycin C on day one and 29 of radiation therapy (EL-2). Alternatively, oral capecitabine at a dose of 825 mg/m^2^ twice daily on each day of radiation can be used[@ref6] (EL-3)3.2.2Radiotherapy: 45 Gy administered as 1.80 Gy per fraction in 25 fractions to the pelvis and inguinal node area + 5.4-9.0 Gy boost to the tumor bed and inguinal node area3.3Metastatic disease. Palliative chemotherapy with 5-fluorouracil and cisplatin[@ref9] (EL-2). Consider palliative radiation to local disease3.4Recurrent disease3.4.1Local recurrence or persistent disease post-chemoradiotherapy:3.4.1.1Persistent disease is defined as positive biopsy at 3 months from end of chemoradiotherapy3.4.1.2Recurrent disease should be biopsy proven3.4.1.3Anal recurrence. Consider abdominoperineal resection[@ref10] (EL-2)3.4.1.4Inguinal lymph nodes recurrence. Consider groin lymph node dissection (EL-3) or groin irradiation if not carried out earlier ± chemotherapy: 5-fluorouraciland mitomycin C[@ref11] (EL-3)3.4.2Distant recurrence: see section 3.33.5Follow up.3.5.1Every 4 months in the first year and every 6 months thereafter for 5 years, then annually with digital rectal examination and inguinal palpation (EL-3)3.5.2CT scan of abdomen and pelvis annually for the first 3 years (EL-3)
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